LiveActive security incident?Get immediate response
CVE Record

CVE-2026-21923: Vulnerability in the Oracle Life Sciences Central Designer product of Oracle Health Sciences Applications (...

Vulnerability in the Oracle Life Sciences Central Designer product of Oracle Health Sciences Applications (component: Platform). The supported version that is affected is 7.0.1.0. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Life Sciences Central Designer. Successful attacks of this vulnerability can result in unauthorized update, insert or delete access to some of Oracle Life Sciences Central Designer accessible data as well as unauthorized read access to a subset of Oracle Life Sciences Central Designer accessible data. CVSS 3.1 Base Score 6.5 (Confidentiality and Integrity impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N).

MediumCVSS 6.5Not KEV-listedUpdated
Discuss exposureBack to CVEs
Glexia's TakeAutomated analysismoderate

Security readout for executives and security teams

Plain-English summary

Oracle Life Sciences Central Designer 7.0.1.0 has a network-accessible HTTP vulnerability that can be exploited without login. A successful attacker could read some accessible data and modify, insert, or delete some data. This matters most for organizations using Central Designer in regulated clinical or life sciences workflows.

Executive priority

Prioritize remediation for any Central Designer 7.0.1.0 instance supporting clinical or regulated data workflows, especially if reachable beyond trusted internal networks. Risk is data integrity and limited confidentiality, not stated service outage.

Technical view

The issue affects Oracle Life Sciences Central Designer, component Platform, supported version 7.0.1.0. Oracle rates it CVSS 3.1 6.5 with AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N. Impact is limited confidentiality and integrity compromise through HTTP, with no availability impact stated.

Likely exposure

Exposure is limited to organizations running Oracle Life Sciences Central Designer 7.0.1.0 where the application is reachable over HTTP by untrusted networks. Internet-facing or broadly accessible internal deployments carry higher practical risk.

Exploitation context

The CVE states exploitation is easy, unauthenticated, and network-based via HTTP. The provided sources do not indicate active exploitation, public exploit code, or inclusion in CISA KEV.

Researcher notes

No CWE is provided in the source bundle. Oracle describes the vulnerable component as Platform but does not include root-cause detail in the supplied summary. Analysis should focus on asset exposure, authentication boundary, HTTP reachability, and vendor advisory confirmation.

Mitigation direction

  • Review Oracle January 2026 Critical Patch Update guidance for this CVE.
  • Apply vendor-recommended updates or fixes for Central Designer 7.0.1.0.
  • Restrict HTTP access to trusted networks until remediation is complete.
  • Monitor Central Designer data changes for unauthorized read, insert, update, or delete activity.

Validation and detection

  • Inventory Oracle Life Sciences Central Designer deployments and confirm version 7.0.1.0 exposure.
  • Verify whether HTTP access is reachable from untrusted networks.
  • Confirm Oracle CPU remediation status for affected systems.
  • Review application and database logs for suspicious unauthenticated access patterns.
Prepared
Confidence
high
Sources
3

Public sources used

Generated from the cited source records. This long-tail analysis has not been individually reviewed by a named human.

Potential ATT&CK relevance

Conservative CVE-to-ATT&CK context

These mappings and lookup hints may be relevant to the vulnerability behavior, CWE, affected product, or exposure path. Glexia-inferred context is not an official MITRE, ATT&CK, CWE, or CVE Program mapping.

ATT&CK lookup starting points

Use these exact CWE pages and searches to review the Glexia ATT&CK library from this CVE's weakness and description context.

cve · low confidence lookup

CVE-2026-21923 mapping review

Open the CVE-to-ATT&CK bridge for reviewed, inferred, or future official mappings tied to this CVE.

Open ATT&CK lookup
Vulnerability profileCVE Program record
Severity
Medium
CVSS
6.5 (3.1)
Known Exploited
No
Published

Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N

Official CVE source material

CNA and ADP enrichment extracted from CVE v5

These fields come from the CVE record and ADP containers, not from Glexia's Take. They preserve time-varying source decisions such as CISA SSVC, KEV status, CVSS metrics, and provider references.

1CVSS vectors
0Timeline events
0ADP providers
2Source links

CVSS vector scores

1 official score

We collect every scored CVSS vector available in the official CNA and ADP containers. When more than one version is present, the table keeps the source vectors side by side instead of collapsing them into the highest score.

ScoreVersionSeverityVectorExploitImpactSource
6.5CVSS 3.1MediumCVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N3.92.5Primary CVE score

Vulnerability scoring details

Base CVSS 3.1 score

6.5Medium
CVSS 3.1 vector shape for CVE-2026-21923Attack VectorAttack ComplexityPrivileges RequiredUser InteractionScopeConfidentiality ImpactIntegrity ImpactAvailability Impact

Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N

Attack Vector
NetworkAdjacentLocalPhysical
Attack Complexity
LowHigh
Privileges Required
NoneLowHigh
User Interaction
NoneRequired
Scope
ChangedUnchanged
Confidentiality Impact
HighLowNone
Integrity Impact
HighLowNone
Availability Impact
HighLowNone

Source materials

Affected products

Products and packages named in the record

VendorProductVersion / packageStatus
Oracle CorporationOracle Life Sciences Central Designer7.0.1.0Listed
Weakness

CWE details

No CWE listed

CWE links open Glexia weakness intelligence pages with official CWE context, developer remediation guidance, and related CVE mappings.